Business Context and Reporting Period
Company: Adtalem Global Education Inc. (Note: Input metadata referenced "Covista Inc.", but the filing text identifies the registrant as Adtalem Global Education Inc., trading as ATGE).
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2025.
Business Overview: Adtalem is a leading healthcare educator in the U.S., operating five institutions: Chamberlain University, Walden University, American University of the Caribbean School of Medicine (AUC), Ross University School of Medicine (RUSM), and Ross University School of Veterinary Medicine (RUSVM). The company serves over 90,000 students across three reportable segments: Chamberlain, Walden, and Medical and Veterinary.
Key Financial Metrics
| Metric | Fiscal Year 2025 | Fiscal Year 2024 |
|---|---|---|
| Revenue | $1,788.3 million | $1,584.7 million |
| Net Income | $237.1 million | $136.8 million |
| Diluted EPS | $6.18 | $3.39 |
| Adjusted Net Income (Non-GAAP) | $255.6 million | $201.8 million |
| Operating Income | $341.5 million | $217.1 million |
| Operating Margin | 19.1% | 13.7% |
| Adjusted EBITDA (Non-GAAP) | $459.7 million | $377.5 million |
| Cash and Cash Equivalents | $199.6 million | $219.3 million |
| Long-Term Debt (Principal) | $558.3 million | $658.3 million |
| Net Cash Provided by Operating Activities | $333.7 million | $288.4 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 12.9% ($203.6 million) driven by growth across all segments. Chamberlain revenue grew 14.6%, Walden grew 16.5%, and Medical and Veterinary grew 3.7%.
- Profitability Surge: Net income increased 73.3% ($100.3 million). This was primarily driven by revenue growth, decreased interest expense, and the elimination of business integration expenses incurred in the prior year.
- Enrollment Trends: Average total student enrollment increased 9.3% at Chamberlain, 13.5% at Walden, and 0.5% at Medical and Veterinary schools.
- Debt Reduction: The company prepaid $100.0 million on its Term Loan B in January 2025. Total long-term debt principal decreased by approximately $100 million.
- Share Repurchases: Adtalem repurchased 2.32 million shares for $213.1 million during fiscal 2025. On May 6, 2025, the Board authorized a new $150.0 million share repurchase program.
Guidance, Outlook, Risks, and Unusual Items
Legislative and Regulatory Risks
- One Big Beautiful Bill Act (OBBBA): Enacted in July 2025, this legislation introduces substantial changes to federal student aid, including increased loan limits for professional programs, the eventual phase-out of Grad PLUS loans, and new aggregate loan caps. It also includes "Do No Harm" provisions that could threaten Title IV eligibility if graduate earnings do not exceed those of bachelor's degree holders.
- Financial Responsibility: Adtalem's composite score for financial responsibility declined to 0.2 in fiscal 2022. Consequently, institutions operate under provisional certification with heightened cash monitoring and are required to post letters of credit. As of June 30, 2025, $179.0 million in letters of credit were outstanding in favor of the U.S. Department of Education (ED).
- Borrower Defense to Repayment: The company faces ongoing risks related to borrower defense claims. ED notified Adtalem of thousands of applications filed by students at various institutions seeking loan forgiveness. Management believes none properly stated a claim, but the outcome remains uncertain.
Unusual Items
- Settlements: Adtalem paid $28.5 million in November 2024 to resolve a class action lawsuit regarding Walden's DBA program. The company received $5.6 million in indemnification from Laureate Education related to this matter.
- Asset Impairments: The company recorded $6.4 million in asset impairments related to operating lease assets and property and equipment.
Investor Verification Checklist
- Regulatory Compliance: Verify the status of ED's "Do No Harm" rulemaking and its potential impact on Title IV eligibility for graduate programs.
- Liquidity Constraints: Confirm the impact of the $179.0 million in letters of credit on the company's borrowing capacity under its $500.0 million revolving credit facility.
- Enrollment Quality: Assess the sustainability of enrollment growth at Chamberlain and Walden in light of increased competition and potential changes to federal loan limits.
- Legal Contingencies: Monitor the resolution of Borrower Defense to Repayment applications and any potential recoupment actions by ED.
- Goodwill Valuation: Review the annual impairment testing for goodwill, particularly for the RUSM reporting unit, which underwent a quantitative assessment.